Mostrar el registro sencillo del ítem

dc.contributor.authorGómez-Farto, Almudena
dc.contributor.authorJiménez-Escobar, Ana Leticia
dc.contributor.authorPérez González, Noelia
dc.contributor.authorCastán, Herminia
dc.contributor.authorClares Naveros, Beatriz 
dc.contributor.authorArias Santiago, Salvador Antonio 
dc.contributor.authorMontero Vílchez, Trinidad
dc.date.accessioned2024-07-30T08:48:33Z
dc.date.available2024-07-30T08:48:33Z
dc.date.issued2024-05-27
dc.identifier.citationGómez Farto, A. et. al. Gels 2024, 10, 370. [https://doi.org/10.3390/gels10060370]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/93619
dc.description.abstractAtopic dermatitis (AD) is a common dermatological disease affecting both children and adults. No drug-free emulgel has been developed and studied in vitro and in vivo for the treatment of AD. The aim of this study was to develop and assess the efficacy of a topical emulgel containing hyaluronic acid, glycerol, Calendula officinalis, Aloe vera, polyphenols and EGF for the concomitant treatment in patients with AD aged over 14. Objective skin barrier function parameters were included, such as transepidermal water loss (TEWL), skin temperature, pH, stratum corneum hydration, skin elasticity and erythema. The subjective opinion of the patients was determined including acceptability, absorption, comfort of use and tolerability, as well as the degree of improvement in patients’ quality of life. We observed an improvement in the subjective parameters studied and statistically significant differences in the objective parameters. Specifically, we found an improvement in TEWL (p = 0.006), erythema (p = 0.008) and hydration (p < 0.001), parameters indicating an improvement in the epidermal barrier. One hundred per cent of patients were satisfied with the product. Therefore, these results suggest that the product may contribute to the treatment of AD.es_ES
dc.description.sponsorshipInstituto de Investigación Biotecnológica, Farmacéutica y Medicamentos Huérfanos, S.L.es_ES
dc.description.sponsorshipCentre for the Development of Industrial Technology (Spain)es_ES
dc.description.sponsorshipProgram FEDER INTERCONECTA (ITC-20181113)es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEmulgeles_ES
dc.subjectAtopic dermatitis es_ES
dc.subjectHyaluronic acides_ES
dc.titleDevelopment of an Emulgel for the Effective Treatment of Atopic Dermatitis: Biocompatibility and Clinical Investigationes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/gels10060370
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional